Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
GBI Research, a leading business intelligence provider, has released its latest research report, ""Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches"". The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).
Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.
Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.
Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes
Ovarian Cancer Treatment Market in Asia-Pacific to Undergo Modest Growth by 2020, says GBI Research
The Asia-Pacific (APAC) therapeutics market for Ovarian Cancer (OC) will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, at a Compound Annual Growth Rate (CAGR) of 5.1%, says business intelligence provider GBI Research.
The company’s latest report* states that Japan held the largest share of the regional OC therapeutics space in 2013, with 62%, followed by China with 16.5%. The other markets making up the APAC region are Australia and India.
The modest growth in APAC’s overall market will be driven primarily by an increase in the region’s prevalent population, especially in India and China, which will rise from 160,099 in 2013 to 187,103 by 2020, at a CAGR of 2.3%.
Sravanthi Addapally, Associate Analyst for GBI Research, says: “Two key unmet needs in OC therapeutics will also encourage APAC market growth over the forecast period. One is an effective drug for patients with platinum-resistant disease and the other is a maintenance therapy to extend disease-free survival after initial and second-line treatment, predominately in platinum-sensitive disease.
“The potential revenues that clinically successful products could achieve will encourage further OC drug development by 2020.”
Addapally adds that the current OC treatment pipeline has a steady number of candidates in both the late and early developmental stages, with indications that new approvals will be sustained up to the end of the forecast period and beyond.
However, the analyst continues: “Although the late-stage pipeline is crowded in terms of molecule numbers, no candidates have shown significant improvement in overall survival. Most of the late-stage products provide minimal clinical benefit to patients, with the best responses being mild-to-moderate improvements in progression-free survival in comparison with the current standard of care.
“While these more promising products are anticipated to gain approval by 2020, their expected high cost and limited clinical benefits, combined with the dominance of generic drugs, will limit their prescription volumes in the four APAC countries. As a result, the overall region will not witness a paradigm shift in its OC treatment markets before 2020,” Addapally concludes.
*Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
This report analyzes OC treatment usage patterns, available drug types, and pipeline and market forecasts. It provides multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the Asia-Pacific countries.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook